Abstract
Disodium-4-chloro-2, 2'-iminodibenzoate, lobenzarit disodium (CCA) is an antirheumatic drug which was developed in Japan, and its effectiveness on patients with rehumatoid arthritis (RA) was confirmed.
It is known that the acting mechanisms of conventionally used antirheumatic drugs to regulate human immunological abnormalities are caused by the macrophage inhibitory action of gold preparations and the inhibitory action of D-penicillamine on helper T-cells. How a new antirheumatic drug acts on the normalization against the immunological abnormalities of RA patients is a rheumatologically important problem. From the above point of view, we investigated the action of CCA on peripheral blood mononuclear cells to compare with those of gold and D-penicillamine.
